News
Synergy Pharmaceuticals Announces Closing of Public Offering of Shares of Common Stock
NEW YORK, April 16, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc.(Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced the closing of its....
Synergy Pharmaceuticals Inc. Announces Pricing of Public Offering of Common Stock
NEW YORK, April 10, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced the pricing....
Synergy Pharmaceuticals Inc. Announces Public Offering of Common Stock
NEW YORK, April 9, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it is....
RESULTATS ANNUELS 2012 : CROISSANCE DE 32% DU CHIFFRE D'AFFAIRES ANNUEL ET RESULTAT NET POSITIF AU 2ND SEMESTRE 2012
Au cours de sa réunion du 28 mars 2013, le Conseil d'administration de Diagnostic Medical Systems (DMS) a arrêté les comptes annuels 2012, clos le 31 décembre 2012, présentés synthétiquement....
Synergy Pharmaceuticals Reports 2012 Fourth Quarter and Full-Year Financial Results
NEW YORK, March 18, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results
Synergy Pharmaceuticals to Present Study Results From Plecanatide Phase IIb/III Trial in Late-Breaking Clinical Abstract at Digestive Disease Week 2013
NEW YORK, March 15, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that study results
DMS ANNONCE UNE INNOVATION TECHNOLOGIQUE MONDIALE POUR LE DIAGNOSTIC DES PATHOLOGIES OSSEUSES
A l'occasion de l'European Congress of Radiology (ECR) 2013 qui débute ce jour à Vienne (Autriche), Diagnostic Medical Systems (DMS) annonce la présentation, en première
Synergy Pharmaceuticals to Begin Trading on The NASDAQ Global Market
NEW YORK, Feb. 11, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its common stock
Synergy Pharmaceuticals Initiates Multiple Ascending Dose Phase Ib Trial in Healthy Volunteers of SP-333, a Second Generation Guanylate Cyclase C Agonist for the Treatment of Ulcerative Colitis
SP-333 Advances to Multiple-Dosing Safety Study
NEW YORK, Jan. 28, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders,
FORTE PROGRESSION DU CHIFFRE D'AFFAIRES EN 2012 : + 32% A 28,0 MILLIONS D'EUROS
En M€ - Normes IFRS
Données consolidées non auditées
2012
2011
Variation
Chiffre d'affaires
28,0
21,3
+ 32%
A l'issue de l'exercice
Synergy Pharmaceuticals Announces Closing of Merger With Callisto Pharmaceuticals
NEW YORK, Jan. 17, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that its previously
Synergy Pharmaceuticals Announces Approval of Merger With Callisto Pharmaceuticals and Other Actions at Annual Meeting of Stockholders
NEW YORK, Jan. 15, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP) ("Synergy") today announced that it convened its annual meeting of stockholders yesterday and it has received
Synergy Announces Positive Results From Plecanatide Phase IIb/III Trial in Patients With Chronic Idiopathic Constipation
Topline Data Show That Plecanatide Met Primary and Key Secondary Endpoints
NEW YORK, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP) today announced that plecanatide, its
Synergy Pharmaceuticals Completes Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Gastrointestinal Diseases
NEW YORK, Dec. 28, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today the successful
Synergy Pharmaceuticals Begins Phase IIb Trial of Plecanatide in Irritable Bowel Syndrome With Constipation (IBS-C)
NEW YORK, Dec. 27, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that dosing has
Synergy Pharmaceuticals Presents Poster on Novel Mechanism of Action of SP-333, an Agonist of Guanylate Cyclase-C for Treatment of Ulcerative Colitis
Scientific Poster Presentation at 2012 Advances in IBD Conference
NEW YORK, Dec. 14, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal
COMMUNIQUE DE MISE À DISPOSITION DE L'INFORMATION FINANCIERE TRIMESTRIELLE AU 30 SEPTEMBRE 2012
Diagnostic Medical Systems (DMS) annonce avoir mis à la disposition du public et déposé auprès de l'Autorité des marchés financiers son information financière
DMS SECURISE LE FINANCEMENT DE SON FORT DEVELOPPEMENT : RECONDUCTION DES FACILITES BANCAIRES DE 4 M EUR JUSQU'A FIN 2013
Au 3ème trimestre 2012, Diagnostic Medical Systems (DMS) a enregistré une croissance de son activité de + 99% par rapport à la même période du précédent
POURSUITE D'UNE CROISSANCE SOUTENUE AU 3EME TRIMESTRE : + 99% - CHIFFRE D'AFFAIRES A NEUF MOIS EN PROGRESSION DE + 65%
En M€ - Normes IFRS – Données non auditées
2012
2011
Variation
Chiffre d'affaires 1er trimestre
4,9
3,5
+ 40%
Chiffre d'affaires 2ème
Synergy Pharmaceuticals Highlights Mechanistic Features of Plecanatide, a Novel Investigational Drug for Chronic Idiopathic Constipation
Scientific Poster Presentations This Week at ACG 2012 and UEG Week
NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal
Synergy Pharmaceuticals to Present Poster on SP-333, an Agonist of Guanylate Cyclase-C, Highlighting a Novel Approach to Treating Ulcerative Colitis in Humans
Scientific Poster Presentation This Week at ACG 2012
NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders
Synergy Pharmaceuticals Initiates Dosing of Healthy Volunteers in Phase I Trial of SP-333, a Second-Generation GC-C Agonist to Treat Ulcerative Colitis
NEW YORK, Oct. 22, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders announced today that on October 19, 2012 the company
Mise à disposition du Rapport financier semestriel 2012
Diagnostic Medical Systems (DMS) annonce, ce jour, avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers (AMF) son
RESULTATS SEMESTRIELS 2012
Au cours de sa réunion du 24 septembre 2012, le Conseil d’administration de Diagnostic Medical Systems (DMS) a arrêté les comptes semestriels 2012, clos le 30 juin 2012, présentés
Synergy Pharmaceuticals Files IND for SP-333, a Developmental Drug for Gastrointestinal Diseases
NEW YORK, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that an Investigational